nejm.org
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM
Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly
better renal responses than placebo in a phase 2 trial involving patients with lupus
nephritis receiving stan...